Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
4 clinical trials · 4 recruiting · OTHER
Trials by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
RECRUITINGNCT06805812
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced...
PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with...
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoEnrolling: 350020 locations
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38
RECRUITINGNCT05621837
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by...
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoEnrolling: 10001 location
MelanomaBreast CancerRenal Cell Carcinoma+4
RECRUITINGPhase 3NCT05316922
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
To offer the possibility of a treatment that could achieve a meaningful reduction in the incidence of post-radiation therapy hypothyroidism. Thyroid dysfunction may develop from a...
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoEnrolling: 681 location
Hypothyroidism; Irradiation
RECRUITINGNCT06408441
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural...
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoEnrolling: 10020 locations
Epithelioid HemangioendotheliomaSarcoma,Soft Tissue